Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. METHO...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:RMD Open
Hlavní autoři: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Wang, Lisy, Chen, Connie, Kwok, Kenneth, Biswas, Pinaki, Shapiro, Andrea, Madsen, Ann, Wollenhaupt, Jürgen
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Rheumatoid Arthritis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722371/
https://ncbi.nlm.nih.gov/pubmed/33127856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001395
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky